More psychedelic research is happening right now than at any other point in the last 50 years. The Multidisciplinary Association for Psychedelic Studies (MAPS) has provided much of the funding and support for this research. They are now moving into unprecedented territory: Phase 3 trials for Food and Drug Administration (FDA) approval of MDMA-assisted psychotherapy.
As legal psychedelic therapy emerges, ethicists urge for more comprehensive frameworks to address sexual abuse
With a checkered history of misconduct, how will psychedelic-assisted therapists be held accountable in the emerging legal field?